Laurence Levine to Microbial Collagenase
This is a "connection" page, showing publications Laurence Levine has written about Microbial Collagenase.
Connection Strength
3.272
-
Characteristics of Men With Peyronie's Disease and Collagenase Clostridium Histolyticum Treatment Failure: Predictors of Surgical Intervention and Outcomes. J Sex Med. 2020 05; 17(5):1005-1011.
Score: 0.702
-
Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie's disease. Int J Impot Res. 2019 Jan; 31(1):15-19.
Score: 0.631
-
Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: a phase 3 open-label study. J Sex Med. 2015 Jan; 12(1):248-58.
Score: 0.486
-
Surgical correction of persistent Peyronie's disease following collagenase clostridium histolyticum treatment. J Sex Med. 2015 Jan; 12(1):259-64.
Score: 0.485
-
Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol. 2012 Jun; 187(6):2268-74.
Score: 0.406
-
Re: Re: Limited success with clostridium collagenase histolyticum following FDA approval for the treatment of Peyronie's disease. Int J Impot Res. 2020 03; 32(2):257-258.
Score: 0.169
-
Contemporary Review of Peyronie's Disease Treatment. Curr Urol Rep. 2018 May 17; 19(7):51.
Score: 0.155
-
Pharmacologic therapy for Peyronie's disease: what should we prescribe? Expert Opin Pharmacother. 2015 Jun; 16(9):1299-311.
Score: 0.126
-
Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's disease. J Sex Med. 2013 Nov; 10(11):2822-31.
Score: 0.112